Ovid Therapeutics Inc. (OVID)
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which is in Phase 2A clinical trials for the treatment of fragile X syndrome; OV329, a GABA aminotransferase inhibitor for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule for treating epilepsies. It also develops OV882, a short hairpin RNA gene therapy for the treatment of angelman syndrome; and OV815 for the treatment of kinesin-family of proteins associated neurological disorder. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, and Northwestern University, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.
$83.04M
Dr. Jeremy Max Levin Ba Zoology, Dphil, Mb Bchir
44.00
New York, NY
May 05, 2017
-2.85
$-0.41
2.10
5.73
-5,241.52%
-2.67
0.01
0.89
140.06
5.73
-25.19%
-33.40%
Similar stocks (6)
Nuvation Bio Inc.
NUVB
Instil Bio, Inc.
TIL
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
NextCure, Inc.
NXTC
ETF Exposure (23)
iShares Micro-Cap ETF
IWC
0.01817%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.007%
iShares Biotechnology ETF
IBB
0.00636%
iShares Russell 2000 Growth ETF
IWO
0.0052%
iShares Russell 2000 ETF
IWM
0.00278%
ProShares Ultra Nasdaq Biotechnology
BIB
0.002333402807822835%
ProShares Ultra Russell2000
UWM
9.942726308478245e-4%
ProShares UltraPro Russell2000
URTY
4.902746768244388e-4%
ProShares Hedge Replication ETF
HDG
4.174823873271477e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
9.112e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Growth Index Fund
VTWG
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%
Similar stocks (6)
Nuvation Bio Inc.
NUVB
Instil Bio, Inc.
TIL
Assembly Biosciences, Inc.
ASMB
CytomX Therapeutics, Inc.
CTMX
Spero Therapeutics, Inc.
SPRO
NextCure, Inc.
NXTC
ETF Exposure (23)
iShares Micro-Cap ETF
IWC
0.01817%
Invesco Nasdaq Biotechnology ETF
IBBQ
0.007%
iShares Biotechnology ETF
IBB
0.00636%
iShares Russell 2000 Growth ETF
IWO
0.0052%
iShares Russell 2000 ETF
IWM
0.00278%
ProShares Ultra Nasdaq Biotechnology
BIB
0.002333402807822835%
ProShares Ultra Russell2000
UWM
9.942726308478245e-4%
ProShares UltraPro Russell2000
URTY
4.902746768244388e-4%
ProShares Hedge Replication ETF
HDG
4.174823873271477e-4%
Dimensional U.S. Core Equity 2 ETF
DFAC
9.112e-5%
Vanguard Balanced Index Fund Institutional Shares
VBAIX
0%
Vanguard Balanced Index Fund Admiral Shares
VBIAX
0%
Vanguard Balanced Index Fund
VBINX
0%
Vanguard Extended Market Index Fund Institutional Shares
VIEIX
0%
Vanguard Institutional Total Stock Market Index Fund Institutional Shares
VITNX
0%
Vanguard Institutional Total Stock Market Index Fund
VITPX
0%
Vanguard Total Stock Market Index Fund
VITSX
0%
Vanguard Russell 3000 Index Fund
VTHR
0%
Vanguard Total Stock Market Index Fund
VTI
0%
Vanguard Total Stock Market Index Fund
VTSAX
0%
Vanguard Russell 2000 Growth Index Fund
VTWG
0%
Vanguard Russell 2000 Index Fund
VTWO
0%
Vanguard Extended Market Index Fund
VXF
0%